Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well combination chemotherapy and
ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs
used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin
hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib
hydrochloride may be an effective treatment for acute lymphoblastic leukemia.